Despite the introduction of novel drugs, cure of multiple myeloma remains rare. Allo-SCT can induce long-term remission, but randomized studies in advanced disease are lacking and the influence of novel drugs remains unclear. In our retrospective analysis of all patients with myeloma allografted in Switzerland, 95 patients were transplanted between 1988 and 2011. Most patients were heavily pre-treated, and 53% received novel drugs before transplant. In all, 51% were allografted after relapse or progression. Transplant trends changed over time with an increase in reduced intensity conditioning and unrelated donors. At the time of analysis 47 patients remained alive, with a median follow-up of survivors of 53 months. Acute GVHD II-IV and chronic GVHD (cGVHD) occurred in 49% and 53%, respectively; TRM at 5 years was 18%. Five-year OS and PFS were 51% and 29%, respectively. Patients who received transplant upfront vs after relapse had a significantly better outcome, as well as those who had a related donor and achieved CR post transplant. We found no impact of pre-treatment with novel drugs or cGVHD. Although long-term remission following allo-SCT can be achieved, GVHD and TRM remain major limitations. Our series suggests that benefit is highest when allo-SCT is used early in the disease.
INTRODUCTION
The introduction of novel drugs has significantly improved the prognosis of multiple myeloma (MM), however, despite prolonged remission, cure remains rare. 1 Allo-SCT has been shown to induce long-term remission, 2 but due to excess morbidity and mortality, this treatment modality is reserved for selected patients. Furthermore, several controlled studies have shown conflicting results and the role of allogeneic transplantation remains unclear. Although in the frontline setting, two trials showed a survival advantage in comparison with autologous transplantation, 3, 4 other trials failed to show a superior survival for allogeneic transplantation. [5] [6] [7] [8] [9] Conclusions are further complicated by varying inclusion criteria, definitions of high-risk status and use of transplant technology.
In addition, while in trials showing a survival advantage 3, 4 transplantation was performed upfront as part of first-line therapy irrespective of risk factors, in clinical practice it is often offered to patients who have refractory disease, high-risk features or have had multiple relapses, situations for which controlled trials have not yet been performed. Moreover, the growing number of novel agents available is making it increasingly difficult to define the role of allogeneic transplant in relapsed or refractory patients. Along with the questions of whether and when a patient will benefit from a transplant, many other unanswered questions remain, including how best to combine transplant with novel agents because little data exist on their impact on allogeneic transplant, as well the most adequate transplant modality, a topic of ongoing debate. 10 With the aim of contributing to some of these unanswered questions, we have performed a retrospective analysis of all consecutive patients with MM who received an allogeneic transplant in Switzerland.
PATIENTS AND METHODS

Study design
We performed a retrospective cohort study of all patients with MM who received an allo-SCT in Switzerland in the three JACIE accredited national transplant centers. Only patients 18 years or older transplanted before March 2011 were included, assuring a minimum of 6 months follow-up in surviving patients. All patients gave written informed consent to the analysis of outcome data.
Data collection
Patients were identified in the Swiss national registry and cross-checked with the respective institutional databases; data were retrieved from the original patient records. Information on patient characteristics included age, sex, date of diagnosis, initial stage, cytogenetics, treatment before allo-SCT and response at the time of allo-SCT. Data on transplant characteristics included date of transplant, type of donor, type of graft, conditioning and GVHD prophylaxis. Outcome variables encompassed grade of GVHD, graft failure, use of DLI, best response, date of relapse, treatment of relapse and survival.
Patient characteristics
Between 1988 and 2011, 95 patients (57 men and 38 women) received an allogeneic transplant at a median of 22 (3-156) months after diagnosis. Median age at diagnosis was 47 (22-66) years. Ig type was IgG (n ¼ 57, 60%), IgA (n ¼ 23, 24%), Bence Jones light-chains (n ¼ 10, 11%) or IgD (n ¼ 5, 5%). International staging system score at diagnosis was 1 (n ¼ 13, 14%), 2 (n ¼ 20, 21%) or 3 (n ¼ 19, 20%), and unavailable in 43 patients. Cytogenetic analysis was unavailable in more than half of the patients and was therefore not further analyzed.
Transplant characteristics are summarized in Table 1 . Before allogeneic transplant, patients had received a median of two lines (1-7) of previous chemotherapy, and between 0 and 3 autologous transplants. Over half of the patients (53%) had received new agents before allogeneic transplant (defined as use of bortezomib, lenalidomide, thalidomide or combinations thereof). In all, 68 patients had had an autologous SCT before allo-SCT. In all, 49% of patients were transplanted upfront, whereas the remaining patients received a transplant following relapse or progressive disease. The majority of patients had an identical sibling donor, and most grafts were peripheral stem cells. Conditioning regimens were myeloablative (34%), reduced intensity (44%) or non-myeloablative (22%).
Definitions
Lines of chemotherapy were defined according to published criteria. 11 Transplant upfront was defined as transplant before first relapse or progression. Non-myeloablative, reduced intensity and myeloablative conditioning were defined according to published criteria. 12 Acute GVHD (aGVHD) and chronic GVHD (cGVHD) were graded according to standard criteria. 13, 14 Disease status was determined according to the International Myeloma Working Group criteria. 15 TRM was defined as death related to the transplant procedure. PFS was defined as time from transplantation until disease progression, relapse, initiation of treatment for persisting disease or death from any cause. OS was defined as time from transplantation until death. The European Group for Blood and Marrow Transplantation (EBMT) risk score was calculated as described by Gratwohl et al. 16 
Statistical analysis
Transplant characteristics were compared using Pearson's w 2 -test. The Kaplan-Meier method was used to estimate the distribution of OS and PFS, 17 whereas the rate of GVHD and TRM were calculated with the cumulative incidence method. The log-rank test was used to compare among groups. A time-dependent Cox-regression model was used to analyze the effect of the time-varying covariates aGVHD, cGVHD and attainment of CR on OS and PFS. An effect was considered to be statistically significant if the P-value was p0.05. Multivariable analyses were conducted using Cox models. Covariates were included in a stepwise forward selection manner. , there was a significant increase in later years in the proportion of transplants performed after relapse or progression vs upfront with 35% and 66%, respectively (P ¼ 0.003). There was also an increase in the proportion of reduced intensity conditioning (RIC) with 52% vs 81% (P ¼ 0.003), and of patients with an unrelated donor (19% vs 43%, P ¼ 0.012).
RESULTS
Transplant practice trends
New agents Fifty patients (53%) had received either thalidomide, bortezomib or lenalidomide at various time periods before allogeneic transplant. In all, 18 patients (19%) had received only one of these agents, whereas 21 patients (22%) had received 2 and 11 patients (12%) had received all three. A total of 38 patients (40%) had been exposed to thalidomide before transplant, 37 (39%) to bortezomib and 16 (17%) to lenalidomide. Owing to the lack of broad availability of novel agents before 2000, the characteristics of patients who had received new agents before transplant vs those who had not are concurrent with the changes over time mentioned above. Patients who had received novel agents before allo-SCT were more likely to have received a transplant after relapse or progression (72% vs 27%, Po0.001), have received 42 lines of chemotherapy before transplant (60% vs 11%, Po0.001), have received RIC (80% vs 51%, P ¼ 0.003), and have an unrelated donor (48% vs 11%, Po0.001). Allogeneic transplantation in multiple myeloma S Gerull et al Graft failure, GVHD and TRM Three patients experienced graft failure; one patient had primary graft failure following a cord blood transplant, and two further patients had secondary graft failure after transitory mixed chimerism. aGVHD occurred in 55 patients, being grade 1 in 8 (9%), grade 2 in 33 (35%), grade 3 in 9 (10%) and grade 4 in 5 patients (5%). The cumulative incidence of grades II-IV aGVHD at day 100 was 49% (95% CI: 39-59%). Of the 87 patients evaluable for cGVHD, 6 (7%) experienced limited cGVHD, and 44 (51%) had extensive cGVHD, with a 5-year cumulative incidence of cGVHD of 53% (95% CI: 43-63%). A total of 18 patients died of TRM, with a 5-year cumulative incidence of TRM of 18% (95% CI: 9-26%). (Table 2 ). Five patients were not evaluable because of early death. Twenty-five patients converted from a PR or very good PR to a CR. A total of 50 patients experienced relapse or progressive disease post-transplant, 1 patient received therapy for persisting disease but did not fulfill the criteria for progressive disease. Relapse treatment is shown in Table 3 .
Donor lymphocyte infusion
With five patients lost to follow-up, the median follow-up duration of survivors was 53 months . At the time of analysis, 47 patients remained alive, with 30 deaths being related to relapse. The Kaplan-Meier estimate of 2-and 5-year PFS was 44% (95% CI: 34-54%) and 29% (95% CI: 19-39%), respectively, with a median PFS of 421 days (Figure 1 ). The Kaplan-Meier estimate of 2-and 5-year OS was 66% (95% CI: 56-76%) and 51% (95% CI: 40-62%), respectively, with a median OS of 5.7 years (Figure 1 ).
Factors influencing survival
In univariate analysis, we found a superior PFS and OS for patients who received a transplant upfront vs following relapse or progressive disease with a 2-year PFS of 63% (95% CI: 49-77%) vs 25% (95% CI: 12-38%) (P ¼ 0.001) and a 2-year OS of 81% (95% CI: 70-92%) vs 52% (95% CI: 37-67%) (P ¼ 0.001) (Figure 2 ).
Further factors with a significant influence on outcome were the number of lines of therapy before transplant with a significantly superior PFS and OS for patients who had received up to two lines of therapy vs three or more (2-year PFS 55% (95% CI: 39-71%) vs 25% (95% CI: 12-38%), P ¼ 0.021 and 2-year OS 73% (95% CI: 62-84%) vs 52% (95% CI: 33-71%) P ¼ 0.005), having a related donor that was associated with a better PFS (2-year PFS 52% (95% CI: 40-64%) vs 25% (95% CI: 12-38%), P ¼ 0.044) and OS (2-year OS 74% (95% CI: 63-85%) vs 48% (95% CI: 29-67%), P ¼ 0.007), and achieving CR after transplant that led to improved PFS (P ¼ 0.003, HR 0.40, 95% CI: 0.22-0.72). We were also able to confirm the prognostic value of the EBMT risk score 16 in our patient cohort, with a 2-year OS for patients with a score of 0-2 Depth of remission at the time of transplant was not associated with a superior outcome when comparing patients who had reached a CR or very good PR vs PR or worse. There was also no difference in PFS and OS for patients who had received new agents before transplant compared with those who had not. Further factors with no influence on outcome were age, year of transplant, number of prior autologous transplants, type of conditioning, T-cell depletion of the graft, age of donor, and aGVHD and cGVHD as a time-dependent variable.
DISCUSSION
Here, we present a retrospective analysis of all recipients of an allogeneic transplant for MM in Switzerland. We found a significant increase in transplant activity over time as well as a shift in transplant characteristics with a higher proportion of RIC as well as patients allografted with advanced disease in later years. These changes are at least in part explained by general changes in allogeneic transplant trends, which have shown a continuous increase in transplant numbers, 18 as well as a significant rise in the use of RIC in the last decade. 19, 20 The growing interest in RIC in myeloma reflects changes in practice following reports of excessively high TRM with myeloablative conditioning. [21] [22] [23] This might also have led clinicians to employ allogeneic transplantation preferentially for patients with more advanced disease.
The toxicity rates we observed with 3% graft failure, 49% grades II-IV aGVHD, 53% cGVHD and 18% 5-year TRM are in accordance with published results.
2,23 After a median follow-up of survivors of over 4 years, we observed a 2-year PFS and OS of 44% and 66%, respectively. Factors with a significant influence on outcome included type of donor, disease stage (transplant upfront rather than after relapse or progression) and achieving a CR posttransplant. Factors that did not influence outcome included having received new agents before transplant, as well as developing cGVHD after transplant.
A similar, albeit larger patient cohort, which included only RIC was described by Crawley et al. 24 In this retrospective EBMT registry study, 229 patients were transplanted using a variety of conditioning regimens with 27% of patients receiving a transplant in first remission. With a 3-year PFS and OS of 21% and 41% of all patients, factors that adversely affected outcome included advanced disease, more than one prior autologous transplant, alemtuzumab conditioning and the absence of cGVHD. Although we have confirmed that advanced disease is an adverse factor, we found no influence of the number of autologous transplants or cGVHD. Possible explanations include the fact that our study included significantly more patients who had received at least two autologous transplants (40% vs 10%), reflecting the increased use of tandem autologous transplantation in the past decade and implying that patients with two prior autologous transplants do not necessarily have more aggressive disease than those with no or one previous autologous transplant. Furthermore, in the study by Crawley et al. 24 a significantly higher proportion of patients had limited cGVHD with 25% vs 8% in our cohort. This is of note as the greatest benefit in OS was observed for patients with limited cGVHD.
A number of other studies have shown a benefit for patients experiencing cGVHD, [25] [26] [27] [28] [29] while other studies did not. 3, 30, 31 This apparent disparity is explained by differences in analyzed cohorts, which include more or less patients with advanced disease, varying intensity of conditioning regimens (with different patterns of GVHD following reduced intensity vs myeloablative transplant), type of donor (mismatched donors lead to more GVHD) and finally the statistical method applied (landmark analysis that might overestimate benefit vs time-dependent Cox model).
In accordance with previous studies, 26, 27 we found an improved PFS for patients who reached a CR post transplant. Although the same has been shown in the setting of autologous transplantation, [32] [33] [34] the meaning of CR in the allogeneic transplantation setting is distinct since the ultimate goal is longterm cure. This is underlined by data showing the prognostic Allogeneic transplantation in multiple myeloma S Gerull et al significance of reaching molecular remission, 35, 36 and suggests that molecular monitoring should be considered after allogeneic transplantation.
The role of allogeneic transplantation in the era of novel agents has been a subject of growing debate. Although more data are becoming available on treatment with novel agents post transplant, [37] [38] [39] little is known about the efficacy of allogeneic transplantation performed after therapy with new agents because the majority of published studies included patients allografted after induction with conventional drugs. We found no impact of pre-treatment with novel agents, and one might very cautiously speculate that the outcome following allogeneic transplantation is not influenced by pre-transplant treatment, or that any influence pre-treatment with novel drugs might be overcome by the availability of new agents post transplant.
Our observation that PFS and OS are superior for patients transplanted early vs following relapse or progression has been reported previously, although the exact definition of advanced disease varies. 23, 24, [40] [41] [42] [43] [44] This is not surprising, because irrespective of the treatment modality analyzed, relapsed and refractory patients will inherently have a shorter PFS and OS than patients in first remission. However, in contrast to earlier studies, new agents were available to most of our patients who relapsed after allogeneic transplantation. Nevertheless, despite the fact that the majority of our patients received new agents at relapse, this could not overcome the adverse prognosis of patients transplanted with advanced disease.
Furthermore, rather than the outcome of allogeneic transplant at various stages of disease, the more relevant clinical question for the individual patient is whether receiving an allogeneic transplant at a given disease stage prolongs survival vs other available treatments or not. For the upfront situation, of seven randomized studies which attempted to answer this question, only two found a survival advantage for allogeneic transplantation. 3, 4 For relapsed or refractory disease, which is the much more common clinical situation in which allogeneic transplantation is considered, randomized studies are unfortunately still lacking. Several authors have performed retrospective analyses with conflicting results. De Lavallade et al. 45 and Patriarca et al.
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described two retrospective donor vs no donor analyses, finding a superior PFS for patients with a donor, however, no difference in OS, while Karlin et al. 30 recently reported an advantage in OS for allogeneic transplant using a propensity score matching method. Finally, a recent abstract described registry data comparing allogeneic vs autologous transplantation as a second transplant following relapse and found a significantly worse PFS and OS for patients who received an allogeneic transplant, 46 however, the groups were not well balanced. Hence, the question of whether allogeneic transplant at relapse prolongs survival currently remains unanswered.
Our study has several limitations including the retrospective nature and the heterogeneous patient cohort. Furthermore, cytogenetic data were unfortunately lacking, precluding an analysis of the influence of high-risk cytogenetics. However, our cohort is remarkable in that it includes a comparatively large number of patients with a long follow-up, which were all transplanted in one country, precluding any center bias as well as assuring uniform data collection.
In summary, despite the caveats of our study, our results once again emphasise that allogeneic transplantation should most likely be considered early in the course of the disease, and that randomized studies evaluating the benefit of allogeneic transplantation at relapse are urgently needed.
